Want to join the conversation?
$HUM said the updated guidance was primarily the result of better-than-anticipated performance year to date for its individual Medicare Advantage and Healthcare Services businesses. This is partially offset by continued challenges in the companyâs individual commercial medical (Individual) business.
No better outlook on $MSFT. Even if the results beat a bit, the stock may move 4 to 6% higher, but won't go above $60.